• October 16, 2020  

    Lymphoblastic Lymphoma—An Overview Bookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2019 comprehensive presentation of lymphoblastic (precursor B-cell and T-cell) lymphoma emphasizes lymph node-predominant involvement in this blood-lymph node diaspora. (Free registration required, written with a physician audience in mind.)

    .

  • October 16, 2020  

    Hodgkin Lymphoma—An Overview Bookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2020 encyclopedic approach to a potentially curable form of lymphoma is richly detailed and specific for all types and stages of Hodgkin lymphoma. (Free registration required, written with a physician audience in mind.)

    .

  • October 10, 2020  

    Novel Developments in the Multimodality Treatment of Esophageal Cancer Bookmark

    George Lundberg, MD

    A special issue of the research journal Annals of Esophagus curated by Contributing Editor George Lundberg, MD.

    This special issue of an academic research journal discusses “multimodality” treatment—the combination of more than one treatment—and how it is used to treat advanced esophageal cancer.

    .

  • October 8, 2020  

    First Approval of Second-Line Therapy for DLBCL Bookmark

    George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    The FDA has granted accelerated approval to tafasitamab (brand name Monjuvi) as a second-line therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), based upon overall responses seen in a clinical trial. This is the first FDA approval of a second-line treatment for this condition. There are few, if any, other options.

    .

  • October 8, 2020  

    Oral Azacitidine Wins FDA Approval for AML Bookmark

    George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved oral azacitidine (brand name Onureg) based on clinical trial results showing a 10-month improvement in overall survival for patients with acute myeloid leukemia who are ineligible for transplant.

    .

  • October 8, 2020  

    Raising the Bar for Myelofibrosis Therapy Development Bookmark

    George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    Myelodysplastic syndrome (MDS) commonly occurs before a patient develops acute leukemia, and is largely unresponsive to therapy. Two new clinical trials are entering phase 3 and may offer some hope.

    .

  • October 8, 2020  

    New Pancreatic Cancer Treatment May Add Years to the Lives of Those Facing Death Bookmark

    George Lundberg, MD

    Article from the Miami Herald curated by Contributing Editor George Lundberg, MD, who notes: 

    The RenovoCath chemotherapy device permits targeted delivery of usual chemotherapy drugs directly into, and limited to, localized but inoperable pancreatic cancers. It is currently being tested in a phase 3 clinical trial.

    .

  • October 1, 2020  

    How an Expert Would Treat His Own Glioblastoma

    With: Al Musella, DPM

    Two years ago, our Curious Dr. George asked Al Musella, DPM, what he would do if he were diagnosed with glioblastoma multiforme (GBM). Here, he revisits that question. Dr. Musella is President of the Musella Foundation For Brain Tumor Research & Information, Inc. Curious Dr. George: You direct an established foundation that supports research and information about brain tumors. What would you do if… Read more »

  • September 9, 2020  

    What’s New in Treatment for Castrate-Resistant Prostate Cancer?

    Emma Shtivelman, PhD

    About 10% to 20% of all prostate cancers are classified as castrate-resistant prostate cancer (CRPC). CRPC occurs when prostate cancer evolves to resist standard treatment with androgen deprivation therapy (ADT), which blocks the production and signaling activity of hormones called androgens (such as testosterone) that fuel the cancer’s growth. Most CRPCs are diagnosed as metastatic (mCRPC), meaning they have already spread beyond the prostate;… Read more »

  • September 1, 2020  

    Ovarian Cancer—An Overview (2020) Bookmark

    George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Medscape has published this excellent, authoritative, comprehensive overview of ovarian cancer, which includes information on diagnosis and treatment. (Written with a physician audience in mind.)

    .